HealthEquity (HQY) vs RB Global (RBA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
HealthEquity (HQY) has outperformed RB Global (RBA) over the past year, gaining 1.0% versus a loss of 20.5%. Over five years, HQY leads with a +47.3% price change compared with +26.2% for RBA. RB Global is the larger company by market cap ($15.90 billion vs $7.66 billion), about 2.1 times the size, while HealthEquity is growing revenue faster (+9.5% vs +7.2%).
On valuation, HealthEquity trades at a lower forward P/E (16.8x vs 17.7x for RB Global). RB Global pays a dividend yielding 1.47%, while HealthEquity does not currently pay one. HealthEquity converts more of its revenue into profit, with a net margin of 16.4% versus 9.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HQY | RBA |
|---|---|---|
| Share price | $92.61 | $85.84 |
| Market cap | $7.66B | $15.90B |
| 1-day change | -0.47% | +2.15% |
| YTD return | +1.57% | -18.31% |
| 1-year return | +1.04% | -20.49% |
| 5-year return | +47.35% | +26.17% |
| P/E ratio (TTM) | 33.43 | 37.00 |
| Forward P/E | 16.84 | 17.72 |
| EPS (TTM) | $2.77 | $2.32 |
| Dividend yield | 0.00% | 1.47% |
| Annual dividend | $0.00 | $1.26 |
| Revenue (latest FY) | $1.31B | $4.59B |
| Revenue growth (YoY) | +9.47% | +7.15% |
| Net income (latest FY) | $215.20M | $428.40M |
| Gross margin | 69.52% | — |
| Operating margin | 24.55% | 15.54% |
| Net margin | 16.38% | 9.33% |
| 52-week high | $107.62 | $119.33 |
| 52-week low | $72.76 | $78.05 |
| Distance from 52-week high | -13.95% | -28.07% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +28.85% | +49.86% |
| Average volume | 841.36K | 1.72M |
| Shares outstanding | 82.72M | 185.20M |
| Employees | 2,814 | 8,000 |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Industry | Business Services | Business Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RB Global is about 2.1 times larger than HealthEquity by market value ($15.90B vs $7.66B).
- HQY has outperformed RBA by 21.5 percentage points over the past year.
- RB Global offers a meaningfully higher dividend yield (1.47% vs 0.00%).
- HealthEquity is more profitable, keeping 16.4 cents of every revenue dollar as net income versus 9.3 cents for RB Global.
About HealthEquity
HQY stock →HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States.
Consumer Discretionary · Business Services · 2,814 employees
About RB Global
RBA stock →RB Global, Inc. operates a marketplace that provides insights, services, and transaction solutions for buyers and sellers of commercial assets and vehicles worldwide.
Consumer Discretionary · Business Services · 8,000 employees
HQY vs RBA FAQ
Which is bigger, HealthEquity or RB Global?
RB Global (RBA) is larger, with a market capitalization of $15.90B compared with $7.66B for HealthEquity (HQY).
Which stock has performed better over the past year, HQY or RBA?
HQY returned +1.04% over the past 12 months, compared with -20.49% for RBA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HQY or RBA?
HQY has the lower trailing P/E at 33.4, versus 37.0 for RBA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, HealthEquity or RB Global?
RB Global pays a dividend yielding 1.47%, while HealthEquity does not currently pay a regular dividend.
Are HealthEquity and RB Global in the same industry?
Yes. Both are classified in the Business Services industry within the Consumer Discretionary sector.